miRNA在胸膜间皮瘤耐药中的作用研究进展  

Research progress on the role of miRNA in drug resistance of pleural mesothelioma

作　　者：王心萌 李锦松 林亚茹 唐洗敏 普元倩 自加吉 熊伟 WANG Xinmeng;LI Jinsong;LIN Yaru;TANG Ximin;PU Yuanqian;ZI Jiaji;XIONG Wei(School of Basic Medical Sciences,Dali University,Yunnan Dali 671000,China;Key Laboratory of Clinical Biochemistry of Yunnan Province,Yunnan Dali 671000,China;Key Laboratory of Insect Biomedicine Research and Development of Yunnan Province,Yunnan Dali 671000,China)

机构地区：[1]大理大学基础医学院,云南大理671000 [2]云南省高校临床生物化学检验重点实验室,云南大理671000 [3]云南省昆虫生物医药研发重点实验室,云南大理671000

出　　处：《中国药房》2024年第22期2832-2836,共5页China Pharmacy

基　　金：国家自然科学基金项目(No.82160516,No.32160167);云南省科技计划项目(No.202101BA070001-282,No.202201AT070004,No.202301AT070023)。

摘　　要：胸膜间皮瘤(PM)是来源于胸膜的一种罕见恶性肿瘤,大多数患者确诊时已为晚期,患者总体生存率低。微RNA(miRNA)作为肿瘤表观遗传修饰的关键调节因子,与PM耐药性之间有着彼此交错的互作网络。PM对化疗药物的耐药机制包括增加药物外流、减少药物摄取、增强DNA修复、改变药物靶点等;对靶向治疗药物的耐药机制则包括激活替代的信号通路、建立有利的肿瘤微环境、触发上皮-间充质转化等。miRNA在上述耐药机制中发挥了重要作用,部分miRNA可增强癌细胞的药物敏感性,但部分miRNA则具有增强耐药性的作用。鉴于这些关键调控作用,通过使用miRNA拮抗剂或miRNA模拟物靶向纠正耐药形成过程中内源性miRNA的表达失调,可能是逆转PM耐药一种有效的治疗策略。Pleural mesothelioma(PM)is a rare malignant tumor originating from the pleura.Most patients are already in the advanced stage at the time of diagnosis,resulting in a low overall survival rate.MicroRNA(miRNA),as key regulators of tumor epigenetic modification,have an intertwined interactive network with PM drug resistance.The mechanisms of drug resistance in PM to chemotherapeutic drugs include increasing drug efflux,reducing drug intake,enhancing DNA repair,and altering drug targets.The mechanisms of resistance to targeted therapy drugs include activating alternative signaling pathways,establishing a favorable tumor microenvironment,and triggering epithelial-mesenchymal transition.MiRNA plays a key part in the aforementioned resistance mechanisms,with some miRNAs promoting the drug sensitivity of cancer cells,while others contribute to increased drug resistance.In light of these key regulatory functions,targeting the dysregulated expression of endogenous miRNAs in the process of resistance formation using miRNA antagonists or miRNA mimics may be an effective therapeutic strategy to reverse drug resistance in PM.

关 键 词：微RNA 胸膜间皮瘤 靶向治疗 耐药 

分 类 号：R734.3[医药卫生—肿瘤] R969[医药卫生—临床医学]